Copay and Financial Assistance
AmeriPharma™ Specialty Care alleviates financial burdens for patients and their families
-
Advanced software locates funding sources to match you with top-dollar foundation programs
-
One of our copay assistance specialists will assist with the application process
-
Automatic updates will be sent to you and your physician on the status of the funding
What Is Jaypirca?
Jaypirca is an anticancer medication, also known by the name of the active component it contains: pirtobrutinib. This medication was recently granted accelerated approval by the FDA for treating refractory or relapsed mantle cell lymphoma (MCL), a form of non-Hodgkin’s lymphoma (NHL), in adult patients. As an accelerated approval medication, Jaypirca fills a medical need for MCL that other medication therapies currently do not meet. However, in order to obtain regular FDA approval, the drug company must complete clinical trials to further confirm the clinical benefit of this medication.
Jaypirca (pirtobrutinib) belongs to the drug class called “BTK inhibitors,” which block the activity of the BTK enzyme and inhibit the abnormal growth of B-cells in MCL. Jaypirca is unique in that it is a non-covalent inhibitor, whereas other treatments for MCL on the market are covalent inhibitors. As a non-covalent inhibitor, Jaypirca targets specific BTK mutations that are becoming resistant to the covalent inhibitors.
What Is Jaypirca Used To Treat?
Jaypirca is used to treat refractory or relapsed mantle cell lymphoma (MCL) in adult patients whose cancer has returned or stopped responding to previous treatments and who have received at least two or more prior therapies, including covalent BTK medicines.
Mantle cell lymphoma (MCL) is a type of blood cancer affecting the lymphatic system and is thought to arise from genetic mutations or changes that occur in B cells, a type of white blood cell that helps the body to fight infection. In MCL, these genetic changes cause the B cells to grow and divide uncontrollably, leading to the formation of a mass of abnormal cells (tumors) in the lymphatic system. MCL usually develops in the lymph nodes but can also spread to other organs, such as the bone marrow, spleen, and gastrointestinal tract.
MCL is a relatively rare type of non-Hodgkin’s lymphoma (NHL), accounting for about 6% of all NHL cases.
Copay and Financial Assistance
AmeriPharma™ Specialty Care alleviates financial burdens for patients and their families
-
Advanced software locates funding sources to match you with top-dollar foundation programs
-
One of our copay assistance specialists will assist with the application process
-
Automatic updates will be sent to you and your physician on the status of the funding
Jaypirca Dosing Information
Jaypirca is currently available in 50 mg and 100 mg tablets. Jaypirca is well tolerated and is only available with a doctor’s prescription.
The initial recommended dose for adults with MCL is 200 mg (two 100 mg tablets) once a day. However, the dosage of Jaypirca can be adjusted according to the patient’s health status. For example, if you have severe kidney impairment, take certain medications, or if you are experiencing an adverse reaction from your current dose of Jaypirca, your doctor may change the dose to decrease side effects.
Overdose
Avoid taking a double dose of Jaypirca to compensate for a missed dose. If you have missed your dose by more than 12 hours, skip that dose and take the next scheduled dose at your regular time prescribed by your doctor.
Jaypirca Side Effects
The possible common side effects that are clinically reported in ≥ 15% of MCL patients after taking Jaypirca include:
- Tiredness or fatigue
- Diarrhea
- Pneumonia
- Musculoskeletal pain (muscle, bone, and joint pain)
- Swelling and bruising
- Shortness of breath (dyspnea)
Moreover, the less common or rare adverse reactions include:
- Infections (including bacterial, viral, or fungal infections)
- Bleeding problems (including blood in urine, stool, or vomiting blood)
- Decreased blood cell counts (including neutropenia, anemia, and thrombocytopenia)
- Atrial fibrillation and flutter (abnormal heart beats or chest discomfort)
- Second primary malignancies (new cancers of the skin or other organs)
Insurances Accepted
We accept Medicare, multi-state Medicaid, Medi-Cal, Blue Shield, and most private insurances. Call us to find out more about your coverage.
Get Started in Minutes
Fill out your information and one of our specialists will call you ASAP.
How Much Can You Save?
Speak with a copay assistance specialist
(877) 778-0318
By submitting, you agree to AmeriPharma’s Terms of Use, Privacy Policy, and Notice of Privacy Practices